Intercept volatility elevated into data Intercept overall option implied volatility of 106 is above its 26-week average of 97 according to Track Data, suggesting large price movement into the expected release of Phase 2b FLINT 72 week data.
Intercept initiated with a Buy, $465 target at UBS UBS analyst Matthew Roden started shares of Intercept Pharmaceuticals with a Buy rating and $465 price target. Roden sees a favorable risk/reward ahead of the approval and commercial launch of the company's obeticholic acid, known as OCA, in primary biliary cirrhosis. Roden also thinks OCA's opportunity in nonalcoholic steatohepatitis is being undervalued at current share levels. Shares of Intercept closed yesterday up $2.53 to $274.44.